Results 271 to 280 of about 5,850,068 (304)
Some of the next articles are maybe not open access.
Remnant lipoproteins and atherosclerotic cardiovascular disease
Clinica Chimica Acta, 2019Lipoproteins are one of the major risk factors for atherosclerotic cardiovascular disease (ASCVD), among which, low-density lipoprotein (LDL) particles have been definitively shown to be causally associated with the development of ASCVD. Additionally, the concept of remnant lipoproteins has emerged as lipoprotein metabolism has been fully investigated.
Hayato Tada +4 more
openaire +2 more sources
Lasers: Applications in Cardiovascular Atherosclerotic Disease
Critical Care Nursing Clinics of North America, 1989Laser angioplasty is a new, yet experimental intervention in the vascular setting. This technique forces artificially stimulated electrons to generate light energy. This energy can be used to achieve tissue abatement by a variety of mechanisms. Reducing resultant complications from this technique is the goal of current laser research.
openaire +2 more sources
Association of epistaxis with atherosclerotic cardiovascular disease
The Laryngoscope, 2018Objectives/HypothesisTo investigate the association between epistaxis and atherosclerotic cardiovascular disease.Study DesignCase‐control cohort study.MethodsThis study included patients from the tertiary‐care ear, nose, and throat department at the University Hospital of Zurich between December 1, 2016 and June 1, 2017.
Kunz, Seraina M +2 more
openaire +3 more sources
Cystatin C in atherosclerotic cardiovascular disease
Clinica Chimica ActaAtherosclerotic cardiovascular disease (ASCVD) remains the leading cause of global mortality. While traditional risk factors are central to prevention, there is a pressing need for novel biomarkers to improve risk stratification and identify individuals with a high burden of disease.
Siarhei A, Dabravolski +5 more
openaire +2 more sources
Current pharmacotherapies for atherosclerotic cardiovascular diseases
Archives of Pharmacal Research, 2019Despite the introduction of statins for lowering LDL-C level, atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death and morbidity worldwide. Combination therapies with statin and other lipid-lowering drugs, including ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have unlocked additive benefits
Jong-Gil, Park, Goo Taeg, Oh
openaire +2 more sources
Early-onset atherosclerotic cardiovascular disease
European Journal of Preventive Cardiologyabstract Recent trends indicate a concerning increase in early-onset atherosclerotic cardiovascular disease (ASCVD) among younger individuals (men aged <55 years women aged <65 years). These findings highlight the pathobiology of ASCVD as a disease process that begins early in life and underscores the need for more ...
Idine Mousavi +7 more
openaire +2 more sources
Inequities in atherosclerotic cardiovascular disease prevention
Progress in Cardiovascular DiseasesAtherosclerotic cardiovascular (CV) disease (ASCVD) prevention encompasses interventions across the lifecourse: from primordial to primary and secondary prevention. Primordial prevention begins in childhood and involves the promotion of ideal CV health (CVH) via optimizing physical activity, body mass index, blood glucose levels, total cholesterol ...
Sofia E, Gomez +2 more
openaire +2 more sources
Periodontal disease and atherosclerotic cardiovascular disease
Vasa, 2013Robert, Berent, Helmut, Sinzinger
openaire +2 more sources